IMCYSE
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eli... minate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
IMCYSE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Liège, Liege, Belgium
Country:
Belgium
Website Url:
http://www.imcyse.com
Total Employee:
11+
Status:
Active
Total Funding:
55.9 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Font Awesome Apache Euro
Current Employees Featured
Founder
Investors List
Biogenosis
Biogenosis investment in Series B - Imcyse
Epimède SA
Epimède SA investment in Series B - Imcyse
Pfizer
Pfizer investment in Series B - Imcyse
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series B - Imcyse
S.R.I.W.
S.R.I.W. investment in Series B - Imcyse
University of Leuven
University of Leuven investment in Series B - Imcyse
SFPI-FPIM
SFPI-FPIM investment in Series B - Imcyse
W.IN.G
W.IN.G investment in Grant - Imcyse
SFPI-FPIM
SFPI-FPIM investment in Series B - Imcyse
Belfius Bank
Belfius Bank investment in Debt Financing - Imcyse
Official Site Inspections
http://www.imcyse.com Semrush global rank: 2.8 M Semrush visits lastest month: 5.78 K
- Host name: cluster006.ovh.net
- IP address: 213.186.33.17
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Imcyse" on Search Engine
About us - Imcyse
From a discovery made at the Catholic University of Leuven (KUL), Imcyse located in Liège (Belgium), is a clinical-stage biopharmaceutical company pioneering the development …See details»
Pipeline - Imcyse
The Company’s robust pipeline currently comprises clinical-stage programs in Type 1 diabetes and Multiple sclerosis as well as pre-clinical programs in Neuromyelitis optica, …See details»
Imcyse - Crunchbase Company Profile & Funding
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune …See details»
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2
Apr 13, 2022 Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of …See details»
Imcyse Announces Completion of Enrollment in Phase 1 Clinical …
Sep 13, 2023 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of …See details»
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 …
Apr 13, 2022 IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple …See details»
Imcyse Announces Start of Phase 1b/2a IMPACT Study in …
Feb 3, 2021 Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of …See details»
Imcyse - EQT Group
May 5, 2024 Imcyse develops active specific immunotherapies for the treatment and prevention of severe chronic diseasesSee details»
Imcyse Company Profile - Office Locations, Competitors, …
Imcyse is a biopharmaceutical company that develops immunotherapies for the treatment and prevention of severe chronic diseases. It offers Imotopes, a platform that blocks the …See details»
News & Events - Imcyse
Mar 14, 2022 Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of Imotopeâ„¢ IMCY-0141 for the Treatment of Multiple Sclerosis. Imcyse joins CLAIMS, a …See details»
Imcyse - Funding, Financials, Valuation & Investors - Crunchbase
Funding. Imcyse has raised a total of. €55.9M. in funding over 4 rounds. Their latest funding was raised on Feb 17, 2021 from a Series B round. Imcyse is funded by 10 investors. …See details»
Imcyse Enters into Research Collaboration and License …
Feb 2, 2021 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of …See details»
Imcyse - Contacts, Employees, Board Members, Advisors
Imcyse has 6 current employee profiles, including Co-Founder & Research & Development Director, Immunology Vincent Carlier.See details»
Imcyse announces a research collaboration with Pfizer Inc. in ...
Jan 8, 2018 Imcyse develops active targeted immunotherapies to treat and cure severe chronic diseases caused by disruptions in the immune system. The Company’s unique …See details»
Imcyse Reports Positive Immune Response from Interim Analysis …
LIÈGE, Belgium, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and …See details»
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT …
Liège, Belgium, March 1, 2023 – Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for …See details»
Imcyse - Crunchbase
Companies like Imcyse include Excision BioTherapeutics, Inovio Pharmaceuticals, and Agenus. Jounce Therapeutics Cambridge , Massachusetts , United States 152 Contacts …See details»
Imcyse | CipherBio
Explore Imcyse's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Imcyse Announces Completion of Enrollment in Phase 1 Clinical …
Liège, Belgium, September 13, 2023 – Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for …See details»
IMCY 0141 - AdisInsight - Springer
Apr 18, 2022 IMCY 0141 is a synthetic peptide being developed by ImCyse (a spin-off from the Catholic University of Leuven) for the treatment of multiple sclerosis. The.See details»